Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gema H. Ibarburu"'
Publikováno v:
Health Science Reports, Vol 7, Iss 10, Pp n/a-n/a (2024)
Abstract Background and Aims The coronavirus disease 2019 (COVID‐19) pandemic has affected the management of inflammatory bowel disease (IBD) patients. Elective operations and surveillance endoscopies were postponed for IBD patients to preserve hea
Externí odkaz:
https://doaj.org/article/30bf30191e9c434191687581429b0126
Autor:
Matthew Anson, Alex E. Henney, Nicholas Broadwell, Sizheng S. Zhao, Gema H. Ibarburu, Gregory Y.H. Lip, John P.H. Wilding, Daniel J. Cuthbertson, Uazman Alam
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102777- (2024)
Summary: Background: Tirzepatide, a novel dual agonist of glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), has demonstrated greater magnitude of weight loss compared to semaglutide in a phase 3 clinical trial. H
Externí odkaz:
https://doaj.org/article/93b14b0a5d844a77bc3a8c1845bb3ae3
Autor:
Matthew Anson, Ayesha Malik, Sizheng S. Zhao, Philip Austin, Gema H. Ibarburu, Shabbar Jaffar, Anupam Garrib, Daniel J. Cuthbertson, Uazman Alam
Publikováno v:
Journal of Diabetes Research, Vol 2024 (2024)
Conclusions: In this real-world study, early, intensive polytherapy, targeting the distinct pathophysiological defects in T2D, is associated with significantly more favourable cardiorenal outcomes, compared to insulin and SU therapy.
Externí odkaz:
https://doaj.org/article/0e8086b536b041868c2b656cdfa25493